Harvard Medical School, Boston, MA, USA.
Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA.
J Crohns Colitis. 2024 Sep 3;18(9):1510-1513. doi: 10.1093/ecco-jcc/jjae052.
Recent studies have shown that up to 53% of patients with inflammatory bowel disease [IBD] screen positive for avoidant/restrictive food intake disorder [ARFID]. There is however concern that ARFID screening rates are over-inflated in patients with active disease. We aimed to evaluate the frequency and characteristics of ARFID symptoms using the Nine Item ARFID Screen [NIAS], and to use another eating disorder measure, the Eating Disorder Examination-Questionnaire 8 [EDE-Q8], to rule-out/characterise other eating disorder cognitive and behavioural symptoms.
Participants included adults with UC who are enrolled in an ongoing cohort study with quiescent UC (Simple Clinical Colitis Activity Index [SCCAI] ≤2 or faecal calprotectin <150 µg/g with corticosteroid-free clinical remission for ≥3 months) at baseline. We used self-reported data on demographics, gastrointestinal medications, medical comorbidities, NIAS scores, and EDE-Q-8 scores.
We included 101 participants who completed the NIAS at their baseline cohort assessment [age 49.9 ± 16.5 years; 55% female]. Eleven participants [11%] screened positively for ARFID on at least one NIAS subscale [n = 8 male]. Up to 30 participants [30%] screened positive for other eating disorder symptoms [EDE-Q-8 Global ≥2.3]. Overall score distributions on the EDE-Q-8 showed that participants scored highest on the Weight Concern and Shape Concern subscales.
Among adults with UC in remission, we found a low rate of ARFID symptoms by the NIAS but a high rate of positive screens for other eating disorder symptoms.
最近的研究表明,高达 53%的炎症性肠病[IBD]患者筛查出回避/限制型食物摄入障碍[ARFID]。然而,人们担心在活动期疾病患者中,ARFID 筛查率过高。我们旨在使用九项 ARFID 筛查量表[NIAS]评估 ARFID 症状的频率和特征,并使用另一种饮食障碍测量工具,即饮食障碍检查问卷 8 项[EDE-Q8],排除/确定其他饮食障碍认知和行为症状。
参与者包括正在参加一项正在进行的队列研究的 UC 成人患者,这些患者在基线时患有缓解期 UC(简单临床结肠炎活动指数[SCCAI]≤2 或皮质类固醇治疗下粪便钙卫蛋白<150 µg/g 且临床缓解持续时间≥3 个月)。我们使用自我报告的数据,包括人口统计学、胃肠道药物、合并症、NIAS 评分和 EDE-Q-8 评分。
我们纳入了 101 名在基线队列评估时完成了 NIAS 的参与者[年龄 49.9±16.5 岁;55%为女性]。11 名参与者[11%]在至少一个 NIAS 亚量表上筛查出 ARFID 阳性[n=8 名男性]。多达 30 名参与者[30%]筛查出其他饮食障碍症状[EDE-Q-8 总分≥2.3]。EDE-Q-8 的总分分布表明,参与者在体重关注和体型关注子量表上得分最高。
在缓解期的 UC 成人中,我们通过 NIAS 发现 ARFID 症状的发生率较低,但其他饮食障碍症状的阳性筛查率较高。